A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells-Reference-Cited by-同舟云学术

A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells

Published:2021-04-16 Issue:16 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Bozza Matthias¹^ORCID,De Roia Alice¹²³⁴,Correia Margareta P.⁵^ORCID,Berger Aileen⁶⁷^ORCID,Tuch Alexandra⁶⁷^ORCID,Schmidt Andreas⁸,Zörnig Inka⁷⁹,Jäger Dirk⁶⁷⁹,Schmidt Patrick⁷⁹¹⁰^ORCID,Harbottle Richard P.¹^ORCID

Affiliation:

1. DNA Vector Laboratory, DKFZ Heidelberg, Im Neuenheimer Feld 242, Heidelberg, Germany.

2. Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKFZ, Heidelberg, Germany.

3. Department of Neurology, Medical Faculty Mannheim, MCTN Heidelberg University, Heidelberg, Germany.

4. Faculty of Bioscience, Heidelberg University, Heidelberg, Germany.

5. Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal.

6. Clinical Cooperation Unit Applied Tumorimmunity, DKFZ Heidelberg, Im Neuenheimer Feld 460, Heidelberg, Germany.

7. National Center for Tumor Diseases, Medical Oncology, Im Neuenheimer Feld 460, Heidelberg, Germany.

8. Proteona, 2 Jurong East St 21, Singapore 609601, Singapore.

9. Department of Medical Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 460, Heidelberg, Germany.

10. GMP & T cell Therapy Unit, DKFZ Heidelberg, Im Neuenheimer Feld 280, Heidelberg, Germany.

Abstract

Autosomally replicating episomal DNA nanovectors allow clinical-scale CAR-T cell manufacturing.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference49 articles.

1. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts

2. Chimeric Antigen Receptor Therapy

3. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia;Maude S. L.;Clin. Adv. Hematol. Oncol.,2018

4. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

5. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T-cell therapy in acute myeloid leukaemia: Novel therapeutic approaches to longstanding challenges;Gene Reports;2024-09

2. Comparison of ionizable lipids for lipid nanoparticle mediated DNA delivery;European Journal of Pharmaceutical Sciences;2024-09

3. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy;Journal of Translational Medicine;2024-08-05

4. Novel chimeric antigen receptors for the effective and safe treatment of NY‐BR‐1 positive breast cancer;Clinical and Translational Medicine;2024-07

5. Steering the course of CAR T cell therapy with lipid nanoparticles;Journal of Nanobiotechnology;2024-06-28